Interesting preprint on the antibody response after ChAdOx1-nCOV (Covishield) and BBV-152 (Covaxin) among Health Care Workers. (N=552 Covishield =456; Covaxin=96)
Both vaccines elicitedđź‘Ťimmune response after 2nd dose. Seropositivity Covishield >Covaxin
medrxiv.org/content/10.110…
A number of factors include Age, Sex. Comorbidity including T2DM and Hypertension influence the antibody titres (Day 21-36 after 2nd dose)
More reasons why we should be eagerly looking forward to the Phase 3 data for Covaxin
Another preprint now online on Immunogenicity of the ChAdOx1 nCoV-19 and the BBV152 Vaccines in Patients with Autoimmune Rheumatic Diseases.
papers.ssrn.com/sol3/papers.cf…
The data also has healthy controls in comparison where the Ab titres have been examined. While small numbers cannot really ascertain the differences, the Median & IQR values show the same trend in Covaxin vs Covishield
And many other issues with the preprint has been summarised journosdiary.com/2021/06/06/cov…
Meanwhile in a parallel universe
A new preprint comparing the neutralization against B.1.351 and B.1.617.2 compared to B.1 with sera of COVID-19 recovered cases and vaccinees of BBV152
biorxiv.org/content/10.110…
Thanks @shananalla for pointing this out.
One cannot but agree to the very fact as stated on conflicts of interest section.
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.